MK-1775

Product Name: MK-1775

Synonyms: 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-;Adavosertib);1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one;Adavosertib (MK-1775);MK-1775(955365-80-7);MK-1775(AZD1775,Adavosertib);2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one;MK-1775

CAS: 955365-80-7

MF: C27H32N8O2

MW: 500.59538

EINECS:

Product Categories: Other APIs;Inhibitors

Mol File: 955365-80-7.mol

MK-1775 Structure

MK-1775 Chemical Properties

Boiling point 723.8±70.0 °C(Predicted)

density 1.292

pka 13.27±0.29(Predicted)

Safety Information

MSDS Information

MK-1775 Usage And Synthesis

Description MK-1775 is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. MK-1775 is a type of biological therapy. It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow. MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.